Alzheimer's disease expert Dr. Robert
Alexander will help shape the future development path
of T3D Therapeutics' lead drug candidate T3D-959 as a potential
disease remedial therapy for Alzheimer's patients.
RESEARCH
TRIANGLE PARK, N.C., July 25,
2024 /PRNewswire/ -- T3D Therapeutics, Inc., a
clinical stage drug development company engaged in the development
of a new orally administered treatment for Alzheimer's disease
(AD), today announced that Dr. Robert
Alexander has joined the Company's Scientific Advisory
Board.
Leading Alzheimer's Expert Joins T3D
Therapeutics' Scientific Advisory Board
CEO John Didsbury states, "As we
advance the clinical development of our drug candidate, T3D-959,
beyond our completed Phase 2 PIONEER trial, Dr. Alexander's
expertise in Alzheimer's drug development and regulatory affairs
will be invaluable."
Dr. Robert Alexander is currently
the Chief Scientific Officer of the Alzheimer's Prevention
Initiative at the Banner Alzheimer's Institute and a Research
Professor in the Department of Psychiatry at the University of Arizona School of Medicine –
Phoenix. Previously, he held
positions as VP in the neuroscience therapeutic area unit at
Takeda, VP and head of clinical for the neuroscience and pain at
Pfizer, VP of clinical for CNS and the pain innovative medicines
unit (iMed) at AstraZeneca, as well as other positions in discovery
medicine and neuroscience at GSK and Merck. Dr. Alexander received
his M.D. degree from The University of
Chicago Pritzker School of Medicine. He is certified by the
American Board of Psychiatry and Neurology and specializes in
psychopharmacology, having conducted or supervised clinical studies
in a broad range of neurologic and psychiatric indications.
"The Phase 2 results of T3D-959 in mild-to-moderate AD patients
are compelling and offer the strong potential to have a positive
impact on this catastrophic disease. I am looking forward to
assisting the Company to help advance this drug to market as
expeditiously as possible," said Dr. Alexander.
About T3D-959: T3D-959, a small molecule, delivered
orally once daily, is a brain-penetrating PPAR delta/gamma dual
nuclear receptor agonist designed to improve both glucose and lipid
metabolism dysfunctions present in AD and other neurodegenerative
disorders.
About T3D Therapeutics, Inc.: T3D
Therapeutics, Inc. is a privately held, Research Triangle Park, NC-based company. The
Company has an exclusive license to T3D-959, its lead product
candidate, and a platform of structurally related molecules. T3D
Therapeutics' mission is to develop and commercialize T3D-959 for
the treatment of Alzheimer's disease.
Forward-Looking Statements: Statements contained in
this release that are not statements of historical fact are
forward-looking statements, including those statements relating to
the Company's expectations regarding clinical studies and
developments, and the future potential of its product candidates,
including T3D-959, and other statements that are predictive in
nature or that depend upon or refer to future events or conditions.
Without limiting the generality of the foregoing, words such as
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain
important risks and uncertainties, and assumptions, which if they
do not materialize or prove incorrect, may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements which may be made in this
release or which are otherwise made by or on behalf of the Company.
Factors which may affect the Company's results include, but are not
limited to, uncertainties and/or unexpected results related to
research and development and clinical testing, the timing, costs
and uncertainty of obtaining any required regulatory approvals,
changes in the regulatory landscape, uncertainties related to
obtaining additional capital as needed to meet the Company's needs
on acceptable terms, or at all, the absence of any guarantee of
product demand, market acceptance or competitive advantage for any
of the Company's product candidates, if approved, and certain
trade, legal, social and economic risks. Any forward-looking
statement in this release speaks only as of the date on which it is
made, and the Company assumes no obligation to update or revise any
such forward-looking statement.
For more information
visit http://www.t3dtherapeutics.com/.
CONTACT:
John Didsbury, Ph.D., CEO
T3D Therapeutics, Inc.
1-919-237-4897
Email: info (at) t3dtherapeutics (dot) com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leading-alzheimers-expert-joins-t3d-therapeutics-scientific-advisory-board-302203810.html
SOURCE T3D Therapeutics, Inc.